Journal
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
Volume 23, Issue 5, Pages 979-994Publisher
SPRINGER
DOI: 10.1007/s11154-022-09735-8
Keywords
Sodium N-(8-[2-hydroxybenzoyl]amino)caprylate; SNAC; Semaglutide; Glucagon-like peptide-1 receptor agonists; GLP-1RA; Type 2 diabetes; Oral; Peptides
Categories
Funding
- Novo Nordisk Inc.
Ask authors/readers for more resources
The development of an oral GLP-1RA, such as semaglutide, is a significant milestone in the treatment of type 2 diabetes. Its unique pharmacokinetic characteristics make it an effective treatment option, providing improved glycemic control and weight reduction for patients.
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and other benefits of GLP-1RAs, their uptake was initially limited by the fact that they could only be administered by injection. Semaglutide is a human GLP-1 analog that has been shown to significantly improve glycemic control and reduce body weight, in addition to improving cardiovascular outcomes, in patients with T2D. First approved as a once-weekly subcutaneous injection, semaglutide was considered an ideal peptide candidate for oral delivery with a permeation enhancer on account of its low molecular weight, long half-life, and high potency. An oral formulation of semaglutide was therefore developed by co-formulating semaglutide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, a well-characterized transcellular permeation enhancer, to produce the first orally administered GLP-1RA. Pharmacokinetic analysis showed that stable steady-state concentrations could be achieved with once-daily dosing owing to the long half-life of oral semaglutide. Upper gastrointestinal disease and renal and hepatic impairment did not affect the pharmacokinetic profile. In the phase III PIONEER clinical trial program, oral semaglutide was shown to reduce glycated hemoglobin and body weight compared with placebo and active comparators in patients with T2D, with no new safety signals reported. Cardiovascular efficacy and safety are currently being assessed in a dedicated outcomes trial. The development of an oral GLP-1RA represents a significant milestone in the management of T2D, providing an additional efficacious treatment option for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available